CNTX logo

Context Therapeutics Inc. Stock Price

NasdaqCM:CNTX Community·US$105.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

CNTX Share Price Performance

US$1.15
0.01 (0.88%)
US$1.15
0.01 (0.88%)
Price US$1.15

CNTX Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
0 Rewards

Context Therapeutics Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$26.4m

Other Expenses

-US$26.4m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.29
0%
0%
0%
View Full Analysis

About CNTX

Founded
2015
Employees
12
CEO
Martin Lehr
WebsiteView website
www.contexttherapeutics.com

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Recent CNTX News & Updates

We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely

Dec 19
We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely

Recent updates

No updates